Neutral endopeptidase inhibitor salt crystal form and preparation method thereof

A technology of crystal form and calcium salt, applied in the field of medicinal chemistry, can solve problems such as undisclosed preparation methods, and achieve the effects of good fluidity, high stability and small electrostatic effect

Active Publication Date: 2016-11-02
SHENZHEN SALUBRIS PHARMA CO LTD
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Chinese patent CN200780034141.3 discloses a preparation process route of compound 1 calcium salt, but does not disclose the specific preparation method. In the production of pharmaceuticals, the use of the dominant crystal form is beneficial to the improvement of quantitative accuracy, the simplification of the synthesis process, Optimization of production environment, quality control of final products, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neutral endopeptidase inhibitor salt crystal form and preparation method thereof
  • Neutral endopeptidase inhibitor salt crystal form and preparation method thereof
  • Neutral endopeptidase inhibitor salt crystal form and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Preparation of Compound 1(A-3)

[0051]

[0052] Dissolve A-1 (300g) in 2400ml of absolute ethanol at room temperature; heat to 62°C, slowly add 140g of thionyl chloride dropwise and then raise the temperature to 65°C for 2.5h; distill under reduced pressure to obtain a white solid, add 1200ml of n-hexane After stirring, evaporate to dryness under reduced pressure, then add 1200ml of n-hexane and beat in ice bath for 60min; filter, rinse the solid with n-hexane, and dry at 35°C for 10h to obtain 246g of white solid (A-2).

[0053] At room temperature, add 246g of A-2 into a flask containing 2460ml of isopropyl acetate (IPAC) and 81.3g of succinic anhydride; add 92g of triethylamine at low temperature, and react at room temperature until A-2 is completely consumed; The solution was then stirred for 10 min, separated, and the organic phase was washed with 1000 ml×6 water until pH=5, and the obtained organic phase containing A-3 was used for subsequent preparation.

Embodiment 2

[0055] Preparation of compound 1 calcium salt (A-5) crystal form.

[0056]

[0057] At room temperature, drop 1.05 equivalent sodium hydroxide aqueous solution (1mol / L) into the organic phase obtained in Example 1, stir at 40°C for 2h, separate the liquids, extract the aqueous phase with 600mL×4 IPAC, and pressurize and rotary evaporate the IPAC to obtain Aqueous solution containing A-4;

[0058] After heating the aqueous solution containing A-4 to 70°C, slowly add calcium chloride aqueous solution (63g calcium chloride dissolved in 300ml water) dropwise at a uniform speed, after the dripping is completed, keep stirring at 90°C for 0.5 hours, then cool down to 50°C, filter, The filter cake was washed with 300 mL of water to obtain a white solid, which was dried under reduced pressure at 50° C. for 12 h to obtain 250 g (purity: 99.66%) of the crystal form of compound 1 calcium salt (A-5).

[0059] The obtained compound 1 calcium salt (A-5) sample is repeatedly detected twic...

Embodiment 3

[0063] Preparation of compound 1 calcium salt (A-5) crystal form.

[0064]

[0065] At room temperature, drop 1.0 equivalent of sodium hydroxide aqueous solution (1mol / L) into the organic phase obtained in Example 1, stir at 40°C for 2 hours, then add 0.05 equivalent of sodium hydroxide aqueous solution, stir for 1 hour, separate the liquids, and use 600 mL of the aqueous phase ×4 IPAC extraction to obtain an aqueous solution containing A-4;

[0066] After heating the aqueous solution containing A-4 to 75°C, slowly add calcium chloride aqueous solution (63g calcium chloride dissolved in 400ml water) dropwise at a uniform speed, after the dripping is completed, keep stirring at 95°C for 0.5 hours, then cool down to 50°C, filter, The obtained white solid was dried under reduced pressure at 60° C. for 8 h to obtain 230 g (purity: 99.26%) of compound 1 calcium salt (A-5) crystal form.

[0067] Gained compound 1 calcium salt (A-5) sample is repeatedly detected twice through X-r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a crystal form of a compound 1 calcium salt and a preparation method thereof. The compound 1 calcium salt crystal form has the advantages of high stability, low electrostatic effect, and good fluidity, etc.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, in particular to a crystal form of a neutral endopeptidase inhibitor salt and a preparation method thereof. Background technique [0002] Compound 1, chemical name: (2R,4S)-5-biphenyl-4-yl-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester, is a neutral endopeptidase inhibitor Drug (NEPi), clinically has natriuretic and diuretic effects. [0003] [0004] Compound 2 is a drug for anti-heart failure developed by Novartis. This compound is a supramolecular complex (complex) formed by valsartan and compound 1 through non-covalent bonds, and has angiotensin Dual action of receptor blockade and neutral endopeptidase inhibition. The results of completed clinical trials show that compound 2 has a better clinical anti-heart failure effect than enalapril, and is an anti-heart failure drug with great market potential. [0005] [0006] In the disclosed method for synthesizing Compoun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07C233/47C07C231/24C07C231/12
CPCC07B2200/13C07C227/20C07C231/02C07C231/12C07C231/24C07C233/47C07C229/34
Inventor 许文杰韩魁元李松华怀杰植建琼
Owner SHENZHEN SALUBRIS PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap